Tracers / [68Ga]Ga-FAPI-74

[68Ga]Ga-FAPI-74

Also written as FAPI-74; Ga-68 FAPI-74
Radionuclide
Ga-68 t½ 67.71 min
Modality
PET
Production route
—
Stage
—
Syntheses indexed
0
Gastrointestinal and colorectal cancerGynaecological cancerHepatobiliary and pancreatic cancerLung cancerProstate cancerThyroid cancerFAP-directed radioligand therapySarcoma (soft tissue and bone)

What it is

Compound class
FAP inhibitor (FAPI) PET tracer
Target / mechanism
Fibroblast activation protein (FAP) PMID 41779297
Clinical application
Various malignancies including pancreatic, sarcoma, colorectal and gastric cancer PMID 41787024
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [68Ga]Ga-FAPI-74, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
—
USP monograph
—
AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impuritiesGe-68 breakthrough
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-FAPI-74.

Get in touch

Notes

Added from reverse module search (stage 6); 8 article(s) with Ga-68. | Stage 28: added indication(s) onc-sarcoma from consolidated missing-rubric review.